Dermapharm Holding Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 4/22/2026)
| Balance Sheet | Total Assets | 2,204,822,000.00 | ROE | 31.49 % |
| Balance Sheet | Total Equity | 694,376,000.00 | ROA | 6.01 % |
| Cashflow | Capital Expenditures | -42,117,000.00 | P/FCF | 14.89 |
| Cashflow | Free Cash Flow | 139,394,000.00 | – | – |
| Cashflow | Operating Cash Flow | 181,511,000.00 | P/CF | 11.43 |
| Income | Earnings per Share (diluted) | 2.46 | Div. Yield | 2.28 % |
| Income | Net Income | 132,412,000.00 | P/E | 15.67 |
| Income | Shares Outstanding | 53,840,000.00 | P/B | 2.99 |
| Income | Total Revenue | 1,164,978,000.00 | P/S | 1.78 |
Ratios calculated on: 10/14/2026
Company Description
Dermapharm Holding SE engages in the healthcare and pharmaceuticals businesses primarily in Europe. It operates through Branded Pharmaceuticals and Other Healthcare Products, and Parallel Import Business segments. It develops, manufactures, and markets generic and over-the-counter (OTC)pharmaceuticals, natural remedies, and other healthcare products. It offers systemic corticoids to treat allergic reactions, skin disease, and inflammation under the Prednisolut brand; Ampho Moronal, an antifungal drug to treat mouth, throat, and gastrointestinal diseases; Solacutan to treat keratinization; Keltican to treat back pain; and Tromcardin to treat cardiac arrhythmia. It also provides Dekristol, a vitamin D compound; sikapur, a dietary supplement to enhance skin, hair, and nails; VITA aktiv B12 Direktsticks, a galenic form of vitamin B12 with protein compounds to enhance energy and performance, and combats fatigue; and vitamin D drops and silica healthcare products under the Hubner brand. In addition, it offers Panthenol Augensalbe JENAPHARM, an eye ointment; other antibiotics or corticosteroid eye ointments and drops under the Prednifluid, Dexafluid, and Oxyteracyclin-Augensalbe JENAPHARM brands; Dienovel, a hormonal oral contraceptives to prevent pregnancy and treat acne; and Lactofem, a lactic acid treatment. Further, it provides drugs to treat bone loss and cardiovascular diseases; Simagel to treat stomach ailments; Temagin pac, a pain medication; and anesthetics under the Xylocitin-loc or Procain JENAPHARM names. Additionally, it imports and sells pharmaceuticals to wholesalers and pharmacies under the axicorp brand; and offers phytopharmaceuticals, homoeopathics, cosmetics, food and body care products, nutritional supplements, and diet and medical devices. It also operates 16 sales outlets and an online shop; and provides related services. The company was founded in 1991 and is headquartered in Grünwald, Germany. The company is a subsidiary of Themis Beteiligungs-AG.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.dermapharm.de
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more